

IVI, Batavia Biosciences sign MoU for vaccine research and development

10 January 2023 | News

To promote joint development of vaccines for global health



The International Vaccine Institute (IVI), a South Korea-based international organisation devoted to vaccines for global health, and Batavia Biosciences (Batavia), a Dutch firm based in Leiden, have signed a memorandum of understanding (MoU) to promote cooperation for vaccine development.

Under the agreement, the two organisations plan to promote joint development of vaccines for global health by actively utilizing IVI's global network and extensive collaboration experience with low- and middle-income countries, as well as Batavia's advanced production and quality control capabilities.

Batavia, acquired by CJ CheilJedang in 2021, is a biopharmaceutical contract development and manufacturing (CDMO) company headquartered in the Netherlands and has process development and manufacturing capabilities in next generation biotherapies including vaccines, oncolytic virotherapies and cell and gene therapies. Recently, Batavia participated in the development of measles and rubella vaccines with the Institut Pasteur de Dakar (IPD), a non-profit organization in Senegal, reflecting its keen interest in global health issues.

Dr Menzo Havenga CEO of Batavia said, "Combining our high cell density, low cost, biopharmaceutical manufacturing technology with IVI's global cooperation network, allows us to expedite the development of vaccines and capacity onshoring in low- and middle-income countries."

Image caption- Dr Jerome Kim (left), Director General of the International Vaccine Institute (IVI) and Dr Menzo Havenga, CEO of Batavia Biosciences